National Institute of Neurological Disorders and Stroke

CND LIFE SCIENCES ADDS TWO ACCOMPLISHED PATHOLOGISTS TO LEADERSHIP TEAM

Retrieved on: 
Thursday, March 24, 2022
Dementia, Pure autonomic failure, National, Organization, Neurodegeneration, Children's Hospital Los Angeles, Synucleinopathy, Diagnosis, Lists of diseases, Growth, CND, Skin, New York University Grossman School of Medicine, Stroke, Research, University of California, Irvine, Pathology, Lewy body, National Institute, Parkinson's disease, Medical director, Marie Cassidy, Ventana Medical Systems, MD, University, Technology, NIH, Human, Multiple system atrophy, UC, Physician, National Institute of Neurological Disorders and Stroke, Genetics, UCLA, Tulane University, Patient, Medical device, Medicine, Medical imaging, Pharmaceutical industry, Medicine, Science

PHOENIX, March 24, 2022 /PRNewswire/ -- CND Life Sciences, Inc. (www.cndlifesciences.com), an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has added two senior pathologists to its core team, Dr. Janine Feng, MD and Dr. Dana Haydel, MD.

Key Points: 
  • Prior to starting at CND, she worked as a pathologist at Roche Tissue Diagnostics (formerly Ventana Medical Systems) for 17 years.
  • "CND is the first commercial laboratory to offer a test that detects synucleinopathies in the skin," said Dr. Feng.
  • "We are thrilled to welcome these accomplished pathologists to our team and are confident that their expertise will be key to our growth as we build upon the success of the Syn-One Test."
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.

PathMaker Neurosystems Initiates U.S. Multi-Center Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity

Retrieved on: 
Monday, March 7, 2022
Disability, Harvard Medical School, Patient, Spaulding Rehabilitation Hospital, Cerebral palsy, Spasticity, NINDS, Food, Safety, Hospital, Lists of diseases, Physical medicine and rehabilitation, U44, FDA, U.S. News & World Report, Rehabilitation, National Institute, Greater Boston, Clinical trial, Spaulding Rehabilitation Hospital Cape Cod, Multiple sclerosis, US Foods, Traumatic brain injury, Technology, News, Federal, ALS, Mass, Brain, National Institute of Neurological Disorders and Stroke, Department, GLOBE, Amyotrophic lateral sclerosis, Pharmaceutical industry, Stroke

It is the first and only neuromodulation device treating muscle spasticity without the need for drugs or surgery.

Key Points: 
  • It is the first and only neuromodulation device treating muscle spasticity without the need for drugs or surgery.
  • This pivotal trial is designed as a multi-center, randomized, double-blind, sham-controlled trial that will evaluate the efficacy and safety of the treatment of post-stroke lower-limb spasticity with MyoRegulator in active versus sham-treated subjects, with expected enrollment of 76 subjects.
  • We are thrilled to be involved in this trial with PathMaker and explore bringing this technology closer to clinical practice.
  • MyoRegulator is expected to be the worlds first non-invasive neuromodulation device to treat muscle spasticity, enabling treatment without the need for drugs or surgery.

Additional Years of Ice Hockey Play May Be Linked to Greater Chance of CTE

Retrieved on: 
Wednesday, March 2, 2022
YouTube, Ageing, Social media, Football, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Research, Tau, American Academy, National, Death, Twitter, Alzheimer's disease, Lists of diseases, Migraine, Concussion, American Academy of Neurology, Alzheimer's Association, MS, Instagram, LinkedIn, Boston University School of Public Health, Parkinson's disease, Chronic traumatic encephalopathy, Autopsy, Hockey, Epilepsy, Boston University School of Medicine, Disease, Association, National Institute, AAN, Stroke, Annual general meeting, Multiple sclerosis, Ice, National Institute on Aging, United States Department of Veterans Affairs, Athlete, CTE, National Institute of Neurological Disorders and Stroke, Nervous system, Department, Brain, Pharmaceutical industry, Medical imaging, Sports equipment, Neurology, Facebook, MD

According to a new preliminary study , each additional year of playing ice hockey may increase a person's chance of developing CTE by about 23%.

Key Points: 
  • According to a new preliminary study , each additional year of playing ice hockey may increase a person's chance of developing CTE by about 23%.
  • Researchers found that each additional year of play corresponded to a 23% increased chance of having CTE.
  • Each additional year of play was also associated with a 15% increased chance for a person progressing one CTE stage.
  • "While the absolute risk for ice hockey players of developing CTE is still unknown, it may be concerning to athletes and their families that we found each year of ice hockey play may increase the odds of developing CTE by 23%," said Mez.

Janssen Launches Refreshed iMaGineMyMG Campaign for People Living With Myasthenia Gravis

Retrieved on: 
Monday, February 28, 2022
Myasthenia gravis, Security (finance), Awareness, American Academy, Janssen Pharmaceuticals, Metabolism, Facebook, Eye, Incidence, Caregiver, GMG, FAQ, Private Securities Litigation Reform Act, Rare disease, Research, National Institute, Muscle, Risk, MuSK protein, National Institute of Neurological Disorders and Stroke, Disease, Johnson & Johnson, LLC, U.S. Securities and Exchange Commission, American Academy of Neurology, Fatigue, Janssen, Pulmonary hypertension, Medication, Human services, Vaccine, Diagnosis, Muscle weakness, Immune system, Antibody, Lists of diseases, Life, Instagram, Patient, Behavior, Eyelid, Annual report, Medicine, United States Department of Health and Human Services, Heart, Science, Stroke, Degenerative disease, Mortality, Pharmaceutical industry, Dietary supplement, Immunology, Neuroscience, Oncology

The site provides useful resources, along with tools for navigating diagnosis, treatment options, and ongoing life with this rare disease."

Key Points: 
  • The site provides useful resources, along with tools for navigating diagnosis, treatment options, and ongoing life with this rare disease."
  • Stay tuned for more community engagement in the coming months with the launch of the refreshed iMaGineMyMG Facebook, Instagram,and Twitterpages.
  • Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Myasthenia Gravis.

Lundquist Institute Investigator Aims to Improve Stroke Recovery with New Granular Biomaterials

Retrieved on: 
Thursday, February 3, 2022
Pennsylvania State University, Media contacts database, Patient, National Institute of Neurological Disorders and Stroke, University, National, Centers for Disease Control and Prevention, Brain, Immunomodulation, Inflammation, Center, BRAIN, Research, Stroke, Lundquist, Lists of diseases, Axon, History of the University of California, Los Angeles, Neurology, National Institutes of Health, Chemical engineering, Doctor of Philosophy, Paralysis, UCLA, Quality of life, Biomedical engineering, National Institute, Pharmaceutical industry

The Centers for Disease Control and Prevention estimate that someone in the United States has a stroke every 40 seconds .

Key Points: 
  • The Centers for Disease Control and Prevention estimate that someone in the United States has a stroke every 40 seconds .
  • According to Dr. Nih, an assistant professor at the University of California Los Angeles (UCLA) and investigator at The Lundquist Institute, if the research project is successful, the use of biomaterials specifically designed to reduce the immune response to stroke while regenerating new vessels in the injured brain, could significantly improve stroke patients recovery and quality of life.
  • Previously, researchers have injected the stroke lesion with a type of engineered biomaterial known as hydrogel materials to aid in tissue repair.
  • However, these biomaterials are not designed specifically to promote angiogenesis and reduce inflammation, limiting how they contribute to stroke recovery.

PsychoGenics’ High Data Security Standards Are Certified by The NIH

Retrieved on: 
Wednesday, January 12, 2022
Mental Health, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, PTSD, Neurodegeneration, Analgesic, Research, NIH, Microdialysis, Risk assessment, Information, PGI, Contract, EEG, Muscular dystrophy, Government, Lists of diseases, National Institute of Neurological Disorders and Stroke, National Institute, PSPP, Industry, National, Program, Sunovion, NINDS, ALS, Psychology, Security, Autism, Depression, Therapy, AI, Epilepsy, Psychiatry, Electrophysiology, Molecular biology, Pharmaceutical industry, Pain

NIH contractors are required to conform to the standards of data/IT security established by the government, including access control, data recovery, auditing, and risk assessment, according to the content of the information produced, stored, and transmitted.

Key Points: 
  • NIH contractors are required to conform to the standards of data/IT security established by the government, including access control, data recovery, auditing, and risk assessment, according to the content of the information produced, stored, and transmitted.
  • PsychoGenics hardened all security protocols and will continue to pressure-test and monitor its information systems.
  • Meeting these security standards for our information systems assures our clients and partners that data shared with us, or produced by us, is handled with the highest standards in the industry.
  • PsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping.

AcuraStem's Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS

Retrieved on: 
Wednesday, December 15, 2021
Motor neuron, Drug discovery, Shi, DOD, Alzheimer's Drug Discovery Foundation, Department of Defense Serum Repository, ALS, Nature Medicine, Unitary state, Alzheimer's disease, Translational medicine, National Institute of Neurological Disorders and Stroke, National, Stroke, Survival, Motor neuron disease, Mace Head Atmospheric Research Station, Safety, Patient, Machine learning, PIKFYVE, Therapy, Pathology, Drug development, Department, Government, Neurodegeneration, Amyotrophic lateral sclerosis, Neuron, Cytoplasm, International Symposium on Endovascular Therapy, Human, Barrow Neurological Institute, Pharmaceutical industry, Dentistry, Medical device, Nature

These improvements were driven by a rescue of motor neuron degeneration and TDP-43 pathology in the treated mice.

Key Points: 
  • These improvements were driven by a rescue of motor neuron degeneration and TDP-43 pathology in the treated mice.
  • Importantly, the data demonstrates that AS-202 is a potent PIKFYVE suppressor with no significant off-target effects in human cells, and was well-tolerated in rodent models at high doses.
  • "The current preclinical data show that AS-202 could translate into an exciting new clinical approach to treating ALS."
  • AcuraStem's iNeuroRx technology platform, which combines patient-derived disease models and human genetic data at scale, has validated Dr. Ichida's discovery in many ALS patient-derived models including both sporadic and multiple, genetically defined forms of ALS.

Dana Foundation Names Khara Ramos, Ph.D., as Vice President

Retrieved on: 
Tuesday, December 14, 2021
Foundation (nonprofit), National Institute of Dental and Craniofacial Research, Bioethics, NIH, Stanford University, Research, Central nervous system, University of California, San Diego, Ethics, Growth, Technology, Engagement, National, Doctor of Philosophy, National Institute, Chronic pain, Science, National Institute of Neurological Disorders and Stroke, Dana Foundation, Multimedia, Humanities, University, Policy, Computational linguistics, Foundation, University of Colorado Denver School of Public Affairs, Health, Lists of diseases, Management, Society, Neuroscience, Stroke, NINDS

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- The Dana Foundation is excited to announce the hire of Khara Ramos, Ph.D., to the new role of Vice President of Neuroscience within Society, effective January 18, 2022.

Key Points: 
  • NEW YORK, Dec. 14, 2021 /PRNewswire/ -- The Dana Foundation is excited to announce the hire of Khara Ramos, Ph.D., to the new role of Vice President of Neuroscience within Society, effective January 18, 2022.
  • "Khara Ramos joins the Dana Foundation at a critical juncture, as we launch programs that advance the intersections of neuroscience with areas such as ethics, law, humanities, arts, and public engagement.
  • Her expertise in the ethical and societal implications of neuroscience will be integral to our mission," said Caroline Montojo, president of the Dana Foundation.
  • The Dana Foundation is dedicated to advancing neuroscience within society by supporting cross-disciplinary intersections such as neuroscience and ethics, law, policy, humanities, and arts.

Global Nerve Repair and Regeneration Market to 2026 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 7, 2021
Biotechnology, General Health, Health, Other Health, Nerve injury, International Diabetes Federation, International Training Centre of the International Labour Organization, Hypoesthesia, Neuroregeneration, Paresthesia, Regeneration, Statistics, Pain, Lists of diseases, Falls, Prevalence, Work, IDF, Pelvis, Hypertension, NINDS, Vaccine, USD, Nerve, Diabetes, Accident, National Institute, Weakness, Numb, CAGR, ILO, Injury, Competitive landscape, Incidence, COVID-19, National Institute of Neurological Disorders and Stroke, Globe, Risk, International Labour Organization, Silviculture, Pet, Logging, Pharmaceutical industry

The "Nerve Repair and Regeneration - Market Insight, Competitive Landscape and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nerve Repair and Regeneration - Market Insight, Competitive Landscape and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, technological advancements in the nerve repair product portfolio and high product approvals in recent times, among others are also some of the factors contributing to the global market growth for nerve repair and regeneration.
  • Nerve Repair and Regeneration Market Dynamics:
    The market for nerve repair and regeneration is gaining momentum at present due to the growing prevalence of lifestyle-associated disorders such as diabetes and hypertension.
  • Furthermore, rising nerve injury cases across the globe is also a key factor responsible for the increased demand for nerve repair and regeneration products thereby fuelling the global nerve repair and regeneration market.

Global Neurological Biomarkers Market (2021-2028): Increased Funding for R&D In Biomarkers Expected to Propel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 3, 2021
Health, Biotechnology, Stroke, Biomarker, Ageing, Time, NIH, Abbott, Medicare, Blue Cross, CAGR, HSC, Diagnosis, Dementia, Awareness, Blue, National Institute of Neurological Disorders and Stroke, Prevalence, Genomics, USD, Parkinson, Central nervous system, University, Parkinson's disease, Brain, National, Physician, National Institute, R, Research, GFAP, University of North Texas Health Science Center, Organization, Asia-Pacific, FDA, CT, Lists of diseases, Lists of countries and territories, Blue Cross Blue Shield Association, Drug development, Disease, Medical imaging, Pharmaceutical industry, Health insurance

The global neurological biomarkers market size is expected to reach USD 16.14 billion by 2028.

Key Points: 
  • The global neurological biomarkers market size is expected to reach USD 16.14 billion by 2028.
  • Increasing funding for the R&D of neurological biomarkers to boost the development of new drugs is expected to accelerate market growth.
  • Moreover, the introduction of novel innovative products for the diagnosis of neurological biomarkers is expected to propel market growth over the forecast period.
  • Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth.